<DOC>
	<DOCNO>NCT00633139</DOCNO>
	<brief_summary>This single center , open-label study patient late infantile MLD . All patient previous treat 26 week phase I trial ( EudraCT number : 2006-005341-11 , NCT00418561 ) . All patient offer continue treatment study protocol receive 13 infusion , whereby patient total 27 infusion Metazym . One infusion give every week . After total 52 week treatment subject continue treatment compassionate use protocol . Safety ( AE/SAE ) monitor every visit .</brief_summary>
	<brief_title>Long-term Metazym Treatment Patients With Late Infantile Metachromatic Leukodystrophy ( MLD )</brief_title>
	<detailed_description />
	<mesh_term>Leukodystrophy , Metachromatic</mesh_term>
	<criteria>The patient Phase I trial must meet follow criterion enrol study . Subject 's legally authorize guardian ( ) must provide sign , inform consent prior perform studyrelated activity ( trialrelated activity procedure would perform normal management subject ) The subject his/her guardian ( ) must ability comply clinical protocol Spasticity severe inhibit transportation Presence know clinically significant cardiovascular , hepatic , pulmonary renal disease medical condition , opinion Investigator , would preclude participation trial Any medical condition serious intercurrent illness , extenuate circumstance , opinion Investigator , would preclude participation trial Use investigational product rhASA within 30 day prior study enrolment currently enrol another study involve clinical investigation</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Metazym</keyword>
	<keyword>Late infantile</keyword>
	<keyword>Metachromatic leukodystrophy</keyword>
	<keyword>Long-term safety</keyword>
</DOC>